Skip to main content
Nature Portfolio logoLink to Nature Portfolio
. 2019 Jan 7;25(7):1604. doi: 10.1038/s41380-018-0311-2

Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Maurizio Fava 1,, Marlene P Freeman 1, Martina Flynn 1, Heidi Judge 1, Bettina B Hoeppner 1, Cristina Cusin 1, Dawn F Ionescu 1, Sanjay J Mathew 2, Lee C Chang 2, Dan V Iosifescu 3, James Murrough 3, Charles Debattista 4, Alan F Schatzberg 4, Madhukar H Trivedi 5, Manish K Jha 5, Gerard Sanacora 6, Samuel T Wilkinson 6, George I Papakostas 1
PMCID: PMC8329695  PMID: 30617276

Correction to:Molecular Psychiatry

10.1038/s41380-018-0256-5

Supplementary Figure 1 and Supplementary Tables 1–4 have been re-uploaded so as to reflect the versions supplied during proofs stage. The publisher apologizes for the error in versioning. The HTML version of the paper has been updated.

Electronic supplementary material

Supplementary Table 1 (25.8KB, xlsx)
Supplementary Figure 1 (294.4KB, docx)

Supplementary information

The online version of this article (10.1038/s41380-018-0311-2) contains supplementary material, which is available to authorized users.

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary Table 1 (25.8KB, xlsx)
Supplementary Figure 1 (294.4KB, docx)

Articles from Molecular Psychiatry are provided here courtesy of Nature Publishing Group

RESOURCES